Bruton's Tyrosine Kinase inhibition by Acalabrutinib does not affect early or advanced atherosclerotic plaque size and morphology in Ldlr-/- mice.

[1]  G. Pasterkamp,et al.  Single-cell T cell receptor sequencing of paired human atherosclerotic plaques and blood reveals autoimmune-like features of expanded effector T cells , 2023, Nature Cardiovascular Research.

[2]  D. Tsiantoulas,et al.  The Spectrum of B Cell Functions in Atherosclerotic Cardiovascular Disease , 2022, Frontiers in Cardiovascular Medicine.

[3]  P. Xie,et al.  Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes , 2021, Frontiers in Cell and Developmental Biology.

[4]  R. Hendriks,et al.  Targeting Bruton’s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies , 2021, Frontiers in Cell and Developmental Biology.

[5]  C. Glass,et al.  Microanatomy of the Human Atherosclerotic Plaque by Single-Cell Transcriptomics , 2020, Circulation research.

[6]  W. Brück,et al.  Inhibition of Bruton’s tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease , 2020, Acta Neuropathologica.

[7]  B. Undem,et al.  Bruton's tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis. , 2020, The Journal of clinical investigation.

[8]  P. Quax,et al.  Flow Cytometry-Based Characterization of Mast Cells in Human Atherosclerosis , 2019, Cells.

[9]  A. Weber,et al.  Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity , 2017, Front. Immunol..

[10]  R. Ulrich,et al.  Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile , 2017, The Journal of Pharmacology and Experimental Therapeutics.

[11]  D. Conrad,et al.  Increased Plasma IgE Accelerate Atherosclerosis in Secreted IgM Deficiency , 2017, Circulation research.

[12]  J. Kuiper,et al.  Novel B-cell subsets in atherosclerosis , 2016, Current opinion in lipidology.

[13]  Maciej Banach,et al.  Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies , 2015, BMC Medicine.

[14]  P. Quax,et al.  Mast cells mediate neutrophil recruitment during atherosclerotic plaque progression. , 2015, Atherosclerosis.

[15]  M. Kersten,et al.  Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy. , 2015, Blood.

[16]  P. Kovanen,et al.  Mast Cells as Effectors in Atherosclerosis , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[17]  P. Quax,et al.  Mast cells in human carotid atherosclerotic plaques are associated with intraplaque microvessel density and the occurrence of future cardiovascular events. , 2013, European heart journal.

[18]  J. Kinet,et al.  The Tetraspanin CD63 Is Required for Efficient IgE-Mediated Mast Cell Degranulation and Anaphylaxis , 2013, The Journal of Immunology.

[19]  Michael L. Wang,et al.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. , 2013, The New England journal of medicine.

[20]  Juthamas Sukbuntherng,et al.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.

[21]  Stephen J Galli,et al.  IgE and mast cells in allergic disease , 2012, Nature Medicine.

[22]  P. Tipping,et al.  Depletion of B2 but Not B1a B Cells in BAFF Receptor-Deficient ApoE−/− Mice Attenuates Atherosclerosis by Potently Ameliorating Arterial Inflammation , 2012, PloS one.

[23]  W. Robinson,et al.  The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells , 2011, Arthritis research & therapy.

[24]  P. Tipping,et al.  Conventional B2 B Cell Depletion Ameliorates whereas Its Adoptive Transfer Aggravates Atherosclerosis , 2010, The Journal of Immunology.

[25]  C. Uyttenhove,et al.  B cell depletion reduces the development of atherosclerosis in mice , 2010, The Journal of experimental medicine.

[26]  Douglas H. Thamm,et al.  The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy , 2010, Proceedings of the National Academy of Sciences.

[27]  M. Jauhiainen,et al.  Mast cells promote atherosclerosis by inducing both an atherogenic lipid profile and vascular inflammation , 2009, Journal of cellular biochemistry.

[28]  J. Rivera,et al.  The tyrosine kinase network regulating mast cell activation , 2009, Immunological reviews.

[29]  F. Moll,et al.  Histological Characterization of Restenotic Carotid Plaques in Relation to Recurrence Interval and Clinical Presentation: A Cohort Study , 2008, Stroke.

[30]  C. Boboila,et al.  The Recirculating B Cell Pool Contains Two Functionally Distinct, Long-Lived, Posttransitional, Follicular B Cell Populations1 , 2007, The Journal of Immunology.

[31]  A. Zernecke,et al.  Perivascular Mast Cells Promote Atherogenesis and Induce Plaque Destabilization in Apolipoprotein E–Deficient Mice , 2007, Circulation.

[32]  P. Kovanen,et al.  Adventitial mast cells connect with sensory nerve fibers in atherosclerotic coronary arteries. , 2000, Circulation.

[33]  R. Callard,et al.  Expression of Bruton's tyrosine kinase protein within the B cell lineage , 1994, European journal of immunology.

[34]  D. Chi,et al.  The human mast cell: an overview. , 2006, Methods in molecular biology.